Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy

European Journal of Neurology

Volumn 14, Issue 3, 2007, Pages 269-275

  Lainez M J A ^a   Galvan J ^b   Heras, J ^b   Vila, C ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Medical Department ^*  (Spain)

Author keywords

Almotriptan; Ergotamine; Migraine; Randomized, double blind clinical trial; Treatment

Indexed keywords

ALMOTRIPTAN; CAFFEINE; ERGOTAMINE;

ADULT; ANALGESIA; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; ENDOCARDIAL DISEASE; FEMALE; HEARING DISORDER; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIGRAINE; MONOTHERAPY; MYOCARDIAL DISEASE; NAUSEA AND VOMITING; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME SERIES ANALYSIS; VALVULAR HEART DISEASE; VESTIBULAR DISORDER;

ACUTE DISEASE; ADULT; CAFFEINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ERGOTAMINE; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; NAUSEA; PATIENT SATISFACTION; PHOSPHODIESTERASE INHIBITORS; PHOTOPHOBIA; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 33847734708     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01594.x     Document Type: Article

References (30)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-657.
2. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35: 387-396.
3. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Current Pain Headache Reports 2003; 7: 55-62.
4. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000; 123: 9-18.
5. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-ht1B/1D receptor agonists. Archives of Neurology 2002; 59: 1084-1088.
6. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. European Neurology 1991; 31: 314-322.
7. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Archives of Neurology 1996; 53: 180-184.
8. Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. International Journal of Clinical Practice 2000; 54: 281-286.
9. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. European Neurology 2002; 47: 99-107.
10. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. European Neurology 2003; 49: 20-29.
11. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004; 24(Suppl. 1): 9-160.
12. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20: 765-786.
13. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39(Suppl. 2): S20-S26.
14. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20: 554-560.
15. Edmeads J. Defining response in migraine: which endpoints are important? European Neurology 2005; 53(Suppl. 1): 22-28.
16. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-658.
17. Sandrini G, Dahlof CG, Mathew N, Nappi G. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. International Journal of Clinical Practice 2005; 59: 1356-1365.
18. Silberstein SD. Migraine. Lancet 2004; 363: 381-391.
19. Fuseau E, Petricoul O, Sabin A, et al. Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clinical Therapeutics 2001; 23: 242-251.
20. Badia X, Magaz S, Gutierrez L, Galvan J. The burden of migraine in Spain: beyond direct costs. Pharmacoeconomics 2004; 22: 591-603.
21. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache 2003; 43: 19-26.
22. Meyler WJ. Side effects of ergotamine. Cephalalgia 1996; 16: 5-10.
23. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-1698.
24. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014.
25. Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003; 60: 1682-1683.
26. Tepper SJ. Safety and rational use of the triptans. Medical Clinics of North America 2001; 85: 959-970.
27. Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Safety 2003; 26: 93-107.
28. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-ht agonists) in the acute treatment of migraine. Headache 2004; 44: 414-425.
29. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opinion on Drug Safety 2003; 2: 123-132.
30. Mathew NT. Efficacy and tolerability of almotriptan in controlled clinical trials. European Neurology 2005; 53(Suppl. 1): 29-33.